148 related articles for article (PubMed ID: 33463945)
1. Improving Therapeutic CD20 Antibodies Requires Insight into Their Mechanism of Action.
Arp AB; Elfrink S; van Spriel AB
Crit Rev Oncog; 2020; 25(3):251-273. PubMed ID: 33463945
[TBL] [Abstract][Full Text] [Related]
2. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors.
Navasardyan I; Bonavida B
Crit Rev Oncog; 2020; 25(3):275-290. PubMed ID: 33463946
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Freeman CL; Sehn L
Curr Oncol Rep; 2018 Nov; 20(12):103. PubMed ID: 30483893
[TBL] [Abstract][Full Text] [Related]
5. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
6. Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.
Prica A; Crump M
Leuk Lymphoma; 2019 Mar; 60(3):573-582. PubMed ID: 30668192
[TBL] [Abstract][Full Text] [Related]
7. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
Safdari Y; Ahmadzadeh V; Farajnia S
Invest New Drugs; 2016 Aug; 34(4):497-512. PubMed ID: 27075017
[TBL] [Abstract][Full Text] [Related]
8. The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
Evers M; Jak M; Leusen JHW
Expert Opin Biol Ther; 2018 Sep; 18(9):973-982. PubMed ID: 30084674
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
Deng CL; Zou J; Song HF
Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
12. ImmunoPET of Malignant and Normal B Cells with
Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
[No Abstract] [Full Text] [Related]
13. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into Membrane Targeting of B Cell Lymphoma.
de Winde CM; Elfrink S; van Spriel AB
Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
[TBL] [Abstract][Full Text] [Related]
16. Binding mechanisms of therapeutic antibodies to human CD20.
Kumar A; Planchais C; Fronzes R; Mouquet H; Reyes N
Science; 2020 Aug; 369(6505):793-799. PubMed ID: 32792392
[TBL] [Abstract][Full Text] [Related]
17. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
